{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:13:56Z","timestamp":1790298836521,"version":"4.1.0"},"reference-count":55,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2024,12,14]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Severe Guillain-Barr\u00e9 syndrome (GBS) patients may not show improvement after a single course of intravenous immunoglobulin (IVIg) therapy. Current treatment options include either a second course of IVIg or therapeutic plasma exchange (TPE). This systematic review aims to evaluate the current literature on the use of a second course of IVIg or TPE in patients who fail to show clinical improvement after the first IVIg course.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched PubMed, Embase and Medline databases up until 26 October 2023. Studies that evaluated adult patients with confirmed GBS who have failed one full course of IVIg and subsequently received either repeat IVIg or TPE were included. Risk of bias was performed using study-specific checklists. A narrative synthesis of results is presented.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 37 articles were identified (1 randomised controlled trial (RCT), 3 observational and 33 case reports\/series), consisting of 422 patients in total. 12 studies evaluated repeat IVIg and 24 studies evaluated TPE after IVIg. There was no superiority of a repeat course of IVIg or TPE in all clinical outcome measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The evidence suggests with a low degree of certainty that there is no beneficial effect of further IVIg in unresponsive GBS. The quality of evidence regarding TPE after IVIg is insufficient to suggest any efficacy due to a lack of RCTs. We recommend standardised case reporting with consideration for a multinational case registry and RCTs to determine the efficacy of TPE after initial IVIg unresponsiveness.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjno-2024-000907","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T13:05:26Z","timestamp":1739365526000},"page":"e000907","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Immunoglobulin unresponsive Guillain-Barr\u00e9 syndrome: rinse or repeat? A systematic review"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-6719","authenticated-orcid":false,"given":"Thomas","family":"Roe","sequence":"first","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1382-2129","authenticated-orcid":false,"given":"Alex","family":"Gordon","sequence":"additional","affiliation":[{"name":"North Bristol NHS Trust, Westbury on Trym, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1004-7174","authenticated-orcid":false,"given":"Nicholas","family":"Gourd","sequence":"additional","affiliation":[{"name":"University Hospitals Plymouth NHS Trust, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5028-5898","authenticated-orcid":false,"given":"Charlotte","family":"Thomas","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4881-3767","authenticated-orcid":false,"given":"James","family":"Ward","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8245-0942","authenticated-orcid":false,"given":"Chinar","family":"Osman","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, UK"},{"name":"Neurology, Wessex Neurological Centre, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0165-3359","authenticated-orcid":false,"given":"Ahilanandan","family":"Dushianthan","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, UK"},{"name":"University of Southampton Faculty of Medicine, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"2025072811571729000_7.1.e000907.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0250-9"},{"key":"2025072811571729000_7.1.e000907.2","doi-asserted-by":"publisher","DOI":"10.1159\/000324710"},{"key":"2025072811571729000_7.1.e000907.3","unstructured":"Verboon C , Doets AY , Galassi G , et al . Current treatment practice of Guillain-Barr\u00e9 syndrome. Neurology (ECronicon) 2019;93."},{"key":"2025072811571729000_7.1.e000907.4","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.3390\/jcm11092451","article-title":"Prolonged Mechanical Ventilation: Outcomes and Management","volume":"11","author":"Huang","year":"2022","journal-title":"J Clin Med"},{"key":"2025072811571729000_7.1.e000907.5","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270707"},{"key":"2025072811571729000_7.1.e000907.6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"The Lancet"},{"key":"2025072811571729000_7.1.e000907.7","unstructured":"Higgins J , Thomas J , Chandler J , et al . Cochrane Handbook for Systematic Reviews of Interventions Version 6.4(Updated August 2023). 2nd edn. Chichester (UK): John Wiley & Sons, 2019."},{"key":"2025072811571729000_7.1.e000907.8","unstructured":"Wells G , Shea B , O\u2019Connell D , et al . 3rd symposium on systematic reviews: beyond the basics. In: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford, UK, 2000: 3\u20135."},{"key":"2025072811571729000_7.1.e000907.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2017-110853"},{"key":"2025072811571729000_7.1.e000907.10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","article-title":"Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial","volume":"20","author":"Walgaard","year":"2021","journal-title":"Lancet Neurol"},{"key":"2025072811571729000_7.1.e000907.11","doi-asserted-by":"crossref","first-page":"120368","DOI":"10.1016\/j.jns.2022.120368","article-title":"Outcomes in Guillain-Barr\u00e9 Syndrome following a second therapeutic cycle - A single-centre retrospective observational study","volume":"441","author":"Faustino","year":"2022","journal-title":"J Neurol Sci"},{"key":"2025072811571729000_7.1.e000907.12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CND.0b013e3181f3dbbf","article-title":"Plasma Exchange After Initial Intravenous Immunoglobulin Treatment in Guillain-Barr\u00e9 Syndrome: Critical Reassessment of Effectiveness and Cost-Efficiency","volume":"12","author":"Oczko-Walker","year":"2010","journal-title":"J Clin Neuromuscul Dis"},{"key":"2025072811571729000_7.1.e000907.13","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-321496"},{"key":"2025072811571729000_7.1.e000907.14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1159\/000348797","article-title":"Unusual presentation of Guillain-Barr\u00e9 syndrome following traumatic bone injuries: report of two cases","volume":"22","author":"Al-Hashel","year":"2013","journal-title":"Med Princ Pract"},{"key":"2025072811571729000_7.1.e000907.15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/nep.12944","article-title":"Long-term complete remission in a patient with focal segmental glomerulosclerosis associated with Guillain-Barre syndrome","volume":"22","author":"Aratani","year":"2017","journal-title":"Nephrology (Carlton)"},{"key":"2025072811571729000_7.1.e000907.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2009.00206.x"},{"key":"2025072811571729000_7.1.e000907.17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0310057X1003800225","article-title":"Plasmapheresis treatment in Guillain-Barr\u00e9 syndrome: potential benefit over intravenous immunoglobulin","volume":"38","author":"Buzzigoli","year":"2010","journal-title":"Anaesth Intensive Care"},{"key":"2025072811571729000_7.1.e000907.18","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1212\/WNL.43.5.1034","article-title":"Human immune globulin infusion in Guillain-Barr\u00e9 syndrome: worsening during and after treatment","volume":"43","author":"Castro","year":"1993","journal-title":"Neurology (ECronicon)"},{"key":"2025072811571729000_7.1.e000907.19","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.neurol.2021.03.003","article-title":"Fulminant Guillain-Barr\u00e9 syndrome complicated by medial medullary infarction","volume":"177","author":"Chen","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"2025072811571729000_7.1.e000907.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-020-03864-4","article-title":"Severe Guillain-Barr\u00e9 syndrome after surgery for multiple fractures: a rare case report with a 5-year follow-up and a brief review of the literature","volume":"22","author":"Chen","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"key":"2025072811571729000_7.1.e000907.21","doi-asserted-by":"crossref","unstructured":"Coomes EA , Haghbayan H , Spring J , et al . Fulminant Guillain-Barr\u00e9 syndrome in a patient with systemic lupus erythematosus. BMJ Case Rep 2019;12. doi:10.1136\/bcr-2018-226634","DOI":"10.1136\/bcr-2018-226634"},{"key":"2025072811571729000_7.1.e000907.22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1526-0968.2004.00183.x","article-title":"Plasmapheresis treatment in Guillain-Barr\u00e9 syndrome: potential benefit over IVIg in patients with axonal involvement","volume":"8","author":"Dada","year":"2004","journal-title":"Ther Apher Dial"},{"key":"2025072811571729000_7.1.e000907.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)24050-X"},{"key":"2025072811571729000_7.1.e000907.24","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/mus.21131","article-title":"Complete recovery of an aged patient with Guillain-Barr\u00e9 syndrome associated with multiple IgM anti-ganglioside antibodies","volume":"38","author":"Furiya","year":"2008","journal-title":"Muscle Nerve"},{"key":"2025072811571729000_7.1.e000907.25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5152\/TJAR.2013.51","article-title":"Guillain-Barr\u00e9 Syndrome and Human Immunodeficiency Virus","volume":"42","author":"Kelebek Girgin","year":"2014","journal-title":"Turk J Anesth Reanim"},{"key":"2025072811571729000_7.1.e000907.26","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1590\/0004-282X20150136","article-title":"Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barr\u00e9 syndrome?","volume":"73","author":"Godoy","year":"2015","journal-title":"Arq Neuropsiquiatr"},{"key":"2025072811571729000_7.1.e000907.27","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.936896","article-title":"A Clinical Case of COVID-19 Vaccine-Associated Guillain-Barr\u00e9 Syndrome","volume":"23","author":"Hilts","year":"2022","journal-title":"Am J Case Rep"},{"key":"2025072811571729000_7.1.e000907.28","article-title":"Course and Treatment of a Rare Neurological Sequelae After COVID-19: Miller Fisher Syndrome","volume":"14","author":"Kara","year":"2022","journal-title":"Cureus"},{"key":"2025072811571729000_7.1.e000907.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-021-02350-1","article-title":"Guillain-Barr\u00e9 syndrome as the first presentation of human immunodeficiency virus infection","volume":"21","author":"Lopes","year":"2021","journal-title":"BMC Neurol"},{"key":"2025072811571729000_7.1.e000907.30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4103\/0972-2327.144040","article-title":"Factors predicting poor outcome in patients with fulminant Guillaine-Barr\u00e9 syndrome","volume":"17","author":"Nithyashree","year":"2014","journal-title":"Ann Indian Acad Neurol"},{"key":"2025072811571729000_7.1.e000907.31","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-018-1104-6","article-title":"Miller Fisher syndrome, Bickerstaff brainstem encephalitis and Guillain-Barr\u00e9 syndrome overlap with persistent non-demyelinating conduction blocks: a case report","volume":"18","author":"Puma","year":"2018","journal-title":"BMC Neurol"},{"key":"2025072811571729000_7.1.e000907.32","doi-asserted-by":"crossref","DOI":"10.1177\/2324709620961198","article-title":"A Case of Guillain-Barr\u00e9 Syndrome Associated With COVID-19","volume":"8","author":"Rajdev","year":"2020","journal-title":"J Investig Med High Impact Case Rep"},{"key":"2025072811571729000_7.1.e000907.33","doi-asserted-by":"crossref","DOI":"10.1186\/s13256-019-2157-x","article-title":"Guillain-Barr\u00e9 syndrome with associated unilateral ptosis without ophthalmoplegia - a rare presentation: a case report and review of the literature","volume":"13","author":"Ralapanawa","year":"2019","journal-title":"J Med Case Rep"},{"key":"2025072811571729000_7.1.e000907.34","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2016.00063","article-title":"A Case of Acute Motor Axonal Neuropathy Mimicking Brain Death and Review of the Literature","volume":"7","author":"Ravikumar","year":"2016","journal-title":"Front Neurol"},{"key":"2025072811571729000_7.1.e000907.35","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008389607293"},{"key":"2025072811571729000_7.1.e000907.36","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.18621\/eurj.461760","article-title":"A new etiology for variant of Guillain-Barr\u00e9 syndrome: bariatric surgery","volume":"5","author":"\u015eahi\u0307n","year":"2019","journal-title":"The Eur Res J"},{"key":"2025072811571729000_7.1.e000907.37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/jca.21783","article-title":"Posterior reversible encephalopathy syndrome associated with Guillain-Barr\u00e9 syndrome: Case report and clinical management considerations","volume":"35","author":"Salvalaggio","year":"2020","journal-title":"J Clin Apher"},{"key":"2025072811571729000_7.1.e000907.38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jocn.2020.01.067","article-title":"Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS)","volume":"74","author":"Shalman","year":"2020","journal-title":"J Clin Neurosci"},{"key":"2025072811571729000_7.1.e000907.39","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/CND.0000000000000076","article-title":"Severe Acute Inflammatory Demyelinating Polyradiculoneuropathy With Persistent Weakness Associated With Tumor-Like Nerve Root Enlargement","volume":"16","author":"Stoll","year":"2015","journal-title":"J Clin Neuromuscul Dis"},{"key":"2025072811571729000_7.1.e000907.40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.20452\/pamw.372","article-title":"Acute respiratory failure in patients with Guillain-Barr\u00e9 syndrome and myasthenic crisis treated with plasmapheresis in the intensive care unit","volume":"118","author":"Szczeklik","year":"2008","journal-title":"Pol Arch Med Wewn"},{"key":"2025072811571729000_7.1.e000907.41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.neucli.2020.09.007","article-title":"Anti-pan-neurofascin IgM in COVID-19-related Guillain-Barr\u00e9 syndrome: Evidence for a nodo-paranodopathy","volume":"50","author":"Tard","year":"2020","journal-title":"Neurophysiol Clin"},{"key":"2025072811571729000_7.1.e000907.42","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3109\/00207454.2015.1033621","article-title":"Guillain-Barr\u00e9 syndrome following chickenpox: a case series","volume":"126","author":"Tatarelli","year":"2016","journal-title":"Int J Neurosci"},{"key":"2025072811571729000_7.1.e000907.43","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jns.2010.01.020","article-title":"Guillain-Barr\u00e9 syndrome as leading manifestation of graft-versus-host disease in an allogeneic bone marrow transplanted patient","volume":"292","author":"Th\u00f6ne","year":"2010","journal-title":"J Neurol Sci"},{"key":"2025072811571729000_7.1.e000907.44","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000358292","article-title":"Successful treatment of refractory Guillain-Barr\u00e9 syndrome with alemtuzumab in a patient with chronic lymphocytic leukemia","volume":"132","author":"Tzachanis","year":"2014","journal-title":"Acta Haematol"},{"key":"2025072811571729000_7.1.e000907.45","article-title":"A Case of Paraneoplastic Guillain-Barr\u00e9 Syndrome Associated with Squamous Cell Carcinoma of the Lung","volume":"10","author":"Wu","year":"2018","journal-title":"Cureus"},{"key":"2025072811571729000_7.1.e000907.46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ensci.2016.08.001","article-title":"Guillain\u2013Barr\u00e9 syndrome after allogeneic bone marrow transplantation: Case report and literature review","volume":"4","author":"Yoshida","year":"2016","journal-title":"eNeurologicalSci"},{"key":"2025072811571729000_7.1.e000907.47","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study","volume":"119 (Pt 4)","author":"Hahn","year":"1996","journal-title":"Brain (Bacau)"},{"key":"2025072811571729000_7.1.e000907.48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jneuroim.2013.01.001","article-title":"Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy - a new mechanism of action?","volume":"256","author":"Bick","year":"2013","journal-title":"J Neuroimmunol"},{"key":"2025072811571729000_7.1.e000907.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2004.04.002"},{"key":"2025072811571729000_7.1.e000907.50","first-page":"S13","article-title":"Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies","volume":"59","author":"Dalakas","year":"2002","journal-title":"Neurology (ECronicon)"},{"key":"2025072811571729000_7.1.e000907.51","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21737"},{"key":"2025072811571729000_7.1.e000907.52","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21705"},{"key":"2025072811571729000_7.1.e000907.53","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2021-002960"},{"key":"2025072811571729000_7.1.e000907.54","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/s10875-010-9398-1","article-title":"Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy","volume":"30 Suppl 1","author":"Tackenberg","year":"2010","journal-title":"J Clin Immunol"},{"key":"2025072811571729000_7.1.e000907.55","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072025","article-title":"Immunoadsorption and Plasma Exchange in Seropositive and Seronegative Immune-Mediated Neuropathies","volume":"9","author":"Davies","year":"2020","journal-title":"J Clin Med"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2024-000907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:57:26Z","timestamp":1753729046000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2024-000907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2,12]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjno-2024-000907"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2024-000907","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}